Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform

Simply Wall St.03-13

Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619152838?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-03-13 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619152838","market":"hk","top_or_hot":-1,"title":"Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform","media":"Simply Wall St.","content":"<div>\n<p>Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-as-new-oncology-study-high\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-as-new-oncology-study-high><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-as-new-oncology-study-high\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-as-new-oncology-study-high","article_id":"2619152838","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-as-new-oncology-study-high","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619152838","pubTimestamp":1773368710,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard in network tests missed for about 12% of patients.\nSee our latest analysis for Tempus AI.\nThe study arrives after a busy few weeks, with Tempus AI striking an expanded multi year collaboration with Merck and a new alliance with NYU Langone Health. Yet the share price has seen a 29.85% 90 day...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK7095":"多种金属与采矿","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4587":"ChatGPT概念","TEM":"Tempus AI","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4528":"SaaS概念","TEMT":"2倍做多TEM ETF-Tradr","BK4551":"寇图资本持仓","BK4611":"AI医疗","BK4613":"AI应用软件","BK4023":"应用软件","BK4543":"AI","BK4121":"生命科学工具和服务"},"translate_title":"评估Tempus AI(TEM)的估值作为新的肿瘤学研究强调了其AI平台的临床影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIYY":0.6,"TEM":1.98,"TEMT":0.6},"content_text":"Tempus AI (TEM) is back in focus after publishing a JCO Precision Oncology study showing its advanced comprehensive genomic profiling tools identified actionable cancer treatment options that standard in network tests missed for about 12% of patients. See our latest analysis for Tempus AI. The study arrives after a busy few weeks, with Tempus AI striking an expanded multi year collaboration with Merck and a new alliance with NYU Langone Health. Yet the share price has seen a 29.85% 90 day share price return decline and a 20.57% year to date share price return decline from US$49.53, while the 1 year total shareholder return of 5% suggests earlier optimism is now cooling as investors reassess growth potential and execution risks. If this kind of precision oncology story has your attention, it can be worth seeing what else is out there through our screener of 34 healthcare AI stocks. With Tempus AI now trading well below recent peaks yet still tied to high profile pharma collaborations and AI driven oncology tools, are you looking at an underappreciated growth story, or a stock where future gains are already priced in? AdvertisementMost Popular Narrative: 36.4% Undervalued Tempus AI’s most followed narrative pegs fair value at about $77.93 per share, well above the latest close at $49.53. This frames a wide valuation gap that investors are now weighing against execution risks and oncology demand.  Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage. Expanding clinical genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long term growth opportunities.  Read the complete narrative. Curious what kind of revenue trajectory, profit margins, and future earnings multiple sit behind that fair value gap? The narrative leans on aggressive top line expansion, margin lift and a rich future valuation that many investors may want to unpack before deciding how they feel about that $77.93 figure. Result: Fair Value of $77.93 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, those assumptions can quickly look stretched if competition pressures pricing or if reimbursement delays slow uptake in higher margin assays and AI services. Find out about the key risks to this Tempus AI narrative. Next Steps With both optimism and caution running through this story, it makes sense to look at the full picture yourself and decide quickly where you stand. You can weigh that balance of concern and opportunity with 2 key rewards and 2 important warning signs. Looking for more investment ideas? If this Tempus AI story has sharpened your thinking, do not stop here. Widening your watchlist with fresh ideas can help you spot opportunities earlier.  Target higher quality at better prices by scanning our list of 48 high quality undervalued stocks that may merit a closer look. Strengthen your income game by reviewing 15 dividend fortresses that could suit a portfolio focused on regular cash returns. Prioritise resilience by checking 68 resilient stocks with low risk scores built around companies with more stable risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619152838","isCrawlerRequest":true}